Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)

Treatment of patients with type 2 Diabetes Mellitus (DM) consists of reducing hyperglycemia through diet, exercise, oral drug therapy or insulin (1). The Thiazolidinedione (TZDs), which include Troglitazone (withdrawn by the FDA), Rosiglitazone, and Pioglitazone, correct hyperglycemia by increasing insulin sensitivity in both the liver (2, 3) and skeletal muscles (4,5). Although TZDs improve glycemic control in type 2 diabetic subjects, when these agents are administered to non-diabetic subjects they do not affect fasting plasma glucose levels. Nolan et al. (6) observed no effect on the plasma glucose levels of non-diabetic subjects treated with Troglitazone 200 mg twice daily.

Clinical trials using TZDs in type 2 diabetic subjects have observed that these agents also favorably impact plasma lipid and lipoprotein concentrations. A recent study comparing the efficacy of adding Metformin (850 mg, once or twice daily) or Troglitazone (200 mg, once or twice daily) to Glyburide (10 mg, twice daily) on glycemic control in type 2 diabetic patients (n=22), reported that after 4 months of treatment, Metformin did not induce significant changes in LDL-C, LDL size, HDL-C, Triglycerides or Plasminogen Activator Inhibitor-1 (PAI-1), but decreased C-reactive protein (CRP) by 33%. Interestingly, Troglitazone increased the size of LDL and the mean LDL-C level (+10%), but decreased the Triglyceride (-22%) and CRP (-60%) concentrations (7). Following eight weeks of treatment with Rosiglitazone (4mg, twice daily) in 243 type 2 diabetic patients, the mean HDL-C increased by 6% and TG by 2%. The increase in the LDL-C concentration (9%) was accompanied by a shift in small, dense LDL to large, buoyant LDL in 52% of the treated subjects. The shift in LDL size occurred independent of a significant Triglyceride reduction, which is in contrast to several studies reporting that increases in LDL size are significantly correlated with a decrease in the plasma concentrations of total and very low density lipoproteins (VLDL) Triglycerides (8-10).

The mechanism involved in the plasma lipid and lipoprotein changes induced by TZDs remains unclear. It is possible that these agents indirectly alter plasma lipid and lipoprotein levels indirectly by improving insulin sensitivity and glycemic control, or directly by influencing lipoprotein synthesis and/or catabolism.

In type 2 Diabetes Mellitus, hepatic synthesis of Triglycerides is increased and peripheral catabolism is decreased. The primary metabolic defect causing the hypertriglyceridemia is peripheral insensitivity to the action of insulin, accompanied by hyperinsulinemia. The insulin insensitivity inhibits the synthesis and activity of lipoprotein lipase and consequently impairs peripheral catabolism of Triglyceride-rich lipoproteins (VLDL and Chylomicrons) (11-12). Since hepatocytes remain sensitive to the action of insulin, the hyperinsulinemia suppresses beta-oxidation and shunts free fatty acids entering the liver into the synthesis of Triglycerides. Therefore, hepatic production of Triglycerides (i.e. VLDL) is increased at the same time peripheral catabolism is impaired. The result is hypertriglyceridemia with a reciprocal decease in HDL-C concentration. By reducing insulin resistance and plasma insulin levels, TZDs would decrease hepatic Triglyceride production and enhance peripheral catabolism of Triglycerides, resulting in plasma reduction and a reciprocal increase in the HDL-C level.

Recently, it has been recognized that circulating levels of Triglyceride and HDL-C are influenced by the activities of Peroxisome Proliferator Activator Receptors (PPARs). PPARs constitute a super family of nuclear hormone receptors and are ligand-activated transcription factors. When activated, they transmit signals from intra-cellular lipid-soluble factors (e.g. fatty acids, hormones, vitamins) to genes in the nucleus by binding to DNA at specific response elements (13). Three distinct PPARs, termed alpha, beta, and gamma modulate intracellular lipid and glucose metabolism through controlling gene expression when activated (14). Specifically when PPAR-alpha is activated, gene expression for the synthesis of ApoC-III, lipoprotein lipase, ApoA-I and ApoA-II are impacted. ApoC-III is a specific inhibitor of peripheral lipoprotein lipase and competes with ApoE for space on the surface of VLDL. Reduced amounts of ApoC-III will result in a larger representation of ApoE on the VLDL particle, and as a consequence, the ApoE mediated hydrolysis of Triglycerides is enhanced. Activation of PPAR-alpha leads to decrease production of ApoC-III, which in turn results in enhanced clearance of Triglycerides. Activation of PPAR-alpha also increases the synthesis of lipoprotein lipase, which increases Triglyceride catabolism. Gene expression for the synthesis of ApoA-I and ApoA-II is also enhanced by activation of PPAR-alpha, resulting in increase in HDL concentration. Fibric acid derivatives (Gemfibrozil and Fenofibrate) induce their Triglyceride lowering and HDL-C augmenting properties by binding to the PPAR-alpha nuclear receptor.